Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Debt / NOTE 0.250% 3/0
-
Market price (% of par)
-
88.39%
-
Total 13F principal
-
$712,881,662
-
Principal change
-
+$159,837,778
-
Total reported market value
-
$631,436,377
-
Number of holders
-
50
-
Value change
-
+$142,081,055
-
Number of buys
-
27
-
Number of sells
-
19
Institutional Holders of HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 as of Q2 2022
As of 30 Jun 2022,
HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 was held by
50 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$712,881,662
in principal (par value) of the bond.
The largest 10 bondholders included
Allianz Asset Management GmbH, CAMDEN ASSET MANAGEMENT L P /CA, Davidson Kempner Capital Management LP, Invesco Ltd., CALAMOS ADVISORS LLC, AVIVA PLC, ADVENT CAPITAL MANAGEMENT /DE/, BlackRock Inc., CITIGROUP INC, and WOLVERINE ASSET MANAGEMENT LLC.
This page lists
50
institutional bondholders reporting positions
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.